A number of therapies have been approved for patients with metastatic melanoma, but responses are often limited and mortality remains high; therefore, new therapeutic options are needed. In a phase I trial, a novel DNA-repair inhibitor, DT01, was evaluated in 23 patients with melanoma skin metastases. DT01 is an injectable oligonucleotide mimic of DNA lesions that sequesters the DNA-repair machinery from lesions in genomic DNA. Thus, DT01 was used in combination with radiotherapy to induce genomic lesions. Dose escalation revealed no dose-limiting toxicities after intratumoural and peritumoural injection of DT01, and a maximum tolerated dose was not reached; grade 1–2 injection-site reactions were the most common adverse events. Evaluation of efficacy at 76 lesions in 21 patients revealed promising objective and complete response rates of 59% and 30%, respectively.
References
Le Tourneau, C. et al. First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. Br. J. Cancer http://dx.doi.org/10.1038/bjc.2016.120 (2016)
Rights and permissions
About this article
Cite this article
Killock, D. DT01 DNA-repair inhibitor shows promise. Nat Rev Clin Oncol 13, 396 (2016). https://doi.org/10.1038/nrclinonc.2016.86
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.86